MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Organogenesis Holdings Operating Cash Flow 2011-2026 | ORGO
Annual Operating Cash Flow Organogenesis Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.2 M | 30.9 M | 24.9 M | 62 M | 5.47 M | -33.5 M | -60.6 M | -3.49 M | -4.87 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 62 M | -60.6 M | 3.88 M |
Quarterly Operating Cash Flow Organogenesis Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -19.9 M | - | - | - | -10.2 M | - | - | - | -5.08 M | - | 17.1 M | 11.6 M | 1.41 M | - | 44 M | 16.2 M | -1.3 M | - | -17.7 M | -26.6 M | -17.3 M | - | -27.1 M | -21.7 M | -9.56 M | - | -43.2 M | -20.2 M | -4.46 M | - | -495 K | -326 K | -126 K | - | -24.5 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 44 M | -43.2 M | -6.14 M |
Operating Cash Flow of other stocks in the Drug manufacturers industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-14.3 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-99.2 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
-166 M | $ 1.25 | -3.02 % | $ 134 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-12.7 M | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
-9.58 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
268 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-34.4 M | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-462 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-43.1 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Eagle Pharmaceuticals
EGRX
|
50.7 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
435 M | - | - | $ 28.9 M |  Irlanda |
 |
OrganiGram Holdings
OGI
|
-28.6 M | $ 1.74 | 0.29 % | $ 402 M | Canada |
 |
Emergent BioSolutions
EBS
|
-206 M | $ 12.94 | -3.14 % | $ 663 M | USA |
 |
Evoke Pharma
EVOK
|
-4.98 M | - | - | $ 36.6 M | USA |
 |
Athenex
ATNX
|
-131 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-46.9 M | $ 21.52 | 0.19 % | $ 2.05 B |  France |
 |
Sundial Growers
SNDL
|
-155 M | $ 1.65 | 0.3 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-88 K | $ 3.65 | -3.44 % | $ 4.53 M | USA |
 |
Evolus
EOLS
|
-18 M | $ 5.61 | -2.35 % | $ 348 M | USA |
 |
Harrow Health
HROW
|
3.84 M | $ 47.21 | -7.51 % | $ 1.54 B | USA |
 |
China Pharma Holdings
CPHI
|
-466 K | $ 1.29 | -4.79 % | $ 22.5 M |  China |
 |
Tilray
TLRY
|
7.91 M | $ 9.15 | 0.26 % | $ 5.65 B | Canada |
 |
Jupiter Wellness
JUPW
|
-7.57 M | - | - | $ 33.6 M | USA |
 |
Bausch Health Companies
BHC
|
1.03 B | $ 7.47 | -3.93 % | $ 2.73 B | Canada |
 |
Lannett Company
LCI
|
-7.12 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-612 K | $ 4.78 | -1.04 % | $ 67.2 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-51.4 M | - | - | $ 193 M | Canada |
 |
Veru
VERU
|
-21.7 M | $ 2.35 | 1.73 % | $ 317 M | USA |
 |
Aurora Cannabis
ACB
|
-211 M | $ 4.25 | -0.47 % | $ 86.3 M | Canada |
 |
Pacira BioSciences
PCRX
|
189 M | $ 23.67 | -9.03 % | $ 1.09 B | USA |
 |
PetIQ
PETQ
|
61.9 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
363 M | $ 14.99 | 1.94 % | $ 2.06 B | USA |
 |
ProPhase Labs
PRPH
|
28.6 M | - | - | $ 5.07 M | USA |
 |
Recro Pharma
REPH
|
-1 M | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
-353 K | $ 1.08 | -0.46 % | $ 4.66 M | USA |
 |
Radius Health
RDUS
|
-22.4 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
-9.41 M | $ 0.94 | -3.6 % | $ 21.9 M | USA |
 |
Relmada Therapeutics
RLMD
|
-51.7 M | $ 4.27 | -3.61 % | $ 129 M | USA |
 |
OptiNose
OPTN
|
-20.5 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
49.6 M | $ 9.12 | -2.04 % | $ 648 M | USA |
 |
PLx Pharma
PLXP
|
-32.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-100 M | $ 5.25 | -1.22 % | $ 214 M | USA |
 |
SCYNEXIS
SCYX
|
60.2 M | $ 0.67 | 0.42 % | $ 32.1 M | USA |
 |
Tricida
TCDA
|
-140 M | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
-159 M | $ 2.09 | 1.46 % | $ 21.8 M | USA |
 |
Viatris
VTRS
|
3 B | $ 12.74 | 1.07 % | $ 15.4 B | USA |
 |
Zomedica Corp.
ZOM
|
-16 M | - | -0.21 % | $ 98 M | USA |